Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lina Inagaki

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
International Cancer Conference Journal|September 27, 2021
Myocardial dysfunction caused by abemaciclib: a case reportTakuya Oyakawa, Lina Inagaki, Zhensheng Hua, et al.
Japanese Journal of Clinical Oncology|March 1, 2015
Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE studyKenji Nakano, Noriko Motoi, Lina Inagaki, et al.
Cancer Cell|December 19, 2020
Utility of Preoperative Computed Tomography Scans for Coronavirus Disease in a Cancer Treatment CenterYukinori Ozaki, Jun Masuda, Akemi Kataoka, et al.
Cancer Reports (Hoboken, N.J.)|February 22, 2023
The impact of obesity and endocrine therapy on the prognosis of premenopausal women with hormone receptor-positive breast cancer: A single-institute retrospective studyYukinori Ozaki, Jun Masuda, Akemi Kataoka, et al.
Molecular and Clinical Oncology|February 20, 2016
Predictive factors of head and neck squamous cell carcinoma patient tolerance to high-dose cisplatin in concurrent chemoradiotherapyKenji Nakano, Yasuyoshi Sato, Takashi Toshiyasu, et al.
Frontiers in Oncology|March 17, 2017
Lenvatinib for Anaplastic Thyroid CancerMakoto Tahara, Naomi Kiyota, Tomoko Yamazaki, et al.
Future Oncology (London, England)|January 15, 2019
A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancerShunji Takahashi, Naomi Kiyota, Tomoko Yamazaki, et al.
Cancer Science|February 24, 2022
Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancerYoon Ming Chin, Tomoko Shibayama, Hiu Ting Chan, et al.
BMC Cancer|January 5, 2022
Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center studyYukinori Ozaki, Yosuke Aoyama, Jun Masuda, et al.
Scientific Reports|March 22, 2022
Assessment of a cancer genomic profile test for patients with metastatic breast cancerIppei Fukada, Seiichi Mori, Naomi Hayashi, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
International Cancer Conference Journal|September 27, 2021
Myocardial dysfunction caused by abemaciclib: a case reportTakuya Oyakawa, Lina Inagaki, Zhensheng Hua, et al.
Japanese Journal of Clinical Oncology|March 1, 2015
Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE studyKenji Nakano, Noriko Motoi, Lina Inagaki, et al.
Cancer Cell|December 19, 2020
Utility of Preoperative Computed Tomography Scans for Coronavirus Disease in a Cancer Treatment CenterYukinori Ozaki, Jun Masuda, Akemi Kataoka, et al.
Cancer Reports (Hoboken, N.J.)|February 22, 2023
The impact of obesity and endocrine therapy on the prognosis of premenopausal women with hormone receptor-positive breast cancer: A single-institute retrospective studyYukinori Ozaki, Jun Masuda, Akemi Kataoka, et al.
Molecular and Clinical Oncology|February 20, 2016
Predictive factors of head and neck squamous cell carcinoma patient tolerance to high-dose cisplatin in concurrent chemoradiotherapyKenji Nakano, Yasuyoshi Sato, Takashi Toshiyasu, et al.
Frontiers in Oncology|March 17, 2017
Lenvatinib for Anaplastic Thyroid CancerMakoto Tahara, Naomi Kiyota, Tomoko Yamazaki, et al.
Future Oncology (London, England)|January 15, 2019
A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancerShunji Takahashi, Naomi Kiyota, Tomoko Yamazaki, et al.
Cancer Science|February 24, 2022
Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancerYoon Ming Chin, Tomoko Shibayama, Hiu Ting Chan, et al.
BMC Cancer|January 5, 2022
Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center studyYukinori Ozaki, Yosuke Aoyama, Jun Masuda, et al.
Scientific Reports|March 22, 2022
Assessment of a cancer genomic profile test for patients with metastatic breast cancerIppei Fukada, Seiichi Mori, Naomi Hayashi, et al.
Pageof 2